BioSpace News Archive

Here’s a look at some of the top COVID-19-related stories for today.

HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, announced the appointment of Mark J. Mulvihill, Ph.D., as Chief Scientific Officer, who brings more than 20 years of experience in drug discovery and development with a focus on small molecule therapies.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that Dr. Iain Stuart, Chief Scientific Officer, will participate in and moderate a scientific panel discussion at the 2 nd Annual JAK Inhibitors Drug Development Digital Event, to take place virtually June 29-July 1, 2021.

Reneo Pharmaceuticals, Inc. joined the broad-market Russell 3000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the close of the markets on June 28, 2021.

Propella Therapeutics, Inc. today announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.

Paratek Pharmaceuticals, Inc. today announced Paratek has delivered the first procurement of NUZYRA to the Biomedical Advanced Research and Development Authority (BARDA).

H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company focused on the field of regenerative medicine, today announced the publication of its clinical observational study titled, “Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy.”

Trial to evaluate safety and efficacy of pitolisant for excessive daytime sleepiness and other non-muscular symptoms in adult patients with type 1 myotonic dystrophy

Babson Diagnostics today announced the closing of $31 million in an oversubscribed Series B funding round, led by Emerald Development Managers , with full participation by existing investors Siemens Healthineers, Prism Ventures, and Lago Consulting Group.

Pear Therapeutics, Inc. today announced the first participant enrolled in the National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN)-0100 study on optimizing retention, duration, and discontinuation strategies for pharmacotherapy treatment of opioid use disorder (OUD), using Pear’s prescription digital therapeutic (PDT) reSET-O®.